Plexus Ventures
Plexus
We help companies identify, evaluate, and negotiate in-licensing opportunities to expand their growth potential and geographic presence.
We advise companies in developing an out-licensing strategy and guide them in maximizing the value of their compounds, products, and technologies.
We help firms identify potential product and company acquisitions, develop deal structures, and negotiate definitive agreements.
We are global experts in pharmaceutical divestments, working with companies to target buyers, generate competition for assets, and maximize proceeds.
GLOBAL PRESENCE world

1-888-PLEXUS0 (753-9870)

info@plexusventures.com
RECENT NEWS
  • December 28, 2009 Plexus Ventures Makes Holiday Donation; Mailing List Selects Recipient
  • December 26, 2009 California Biotechs Have Essential Ingredients for Success; Attract Investment from Japanese Firms
  • November 24, 2009 Can Fite BioPharma retains Plexus Ventures to Partner their Phase II Lead Compound, Developed for Psoriasis and Other Indications
  • September 9, 2009 EUSA retains Plexus Ventures to manage the divestment of global rights to ProstaScint®
PharmaTimes World News
  • December 31, 1969FDA OKs wider use of AstraZeneca’s Crestor
  • December 31, 1969Novartis buys rights to Debiopharm's hep C drug
  • December 31, 1969Cost-cutting and emerging markets key for Europe's drugmakers
  • December 31, 1969Study to look at earlier use of MS drug Tysabri
  • December 31, 1969Alzheimer's drug Dimebon may help Huntington's patients
Home | About | Services | Track Record | News Room | Contact | Japanese Japanese Language
  • Overview
  • Our Approach
  • Our History
  • Our Team
  • Our Offices
  • Overview
  • In-Licensing
  • Out-Licensing
  • Acquisitions
  • Divestments
  • Overview
  • Case Studies
  • Client List
  • Press Releases
  • Articles & Presentations
  • Media Inquiries